Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase. In this Phase I trial, patients with advanced solid malignancies were treated with escalating do...

Full description

Bibliographic Details
Main Authors:	Schwartz, G, Carvajal, R, Midgley, R, Rodig, S, Stockman, P, Ataman, O, Wilson, D, Das, S, Shapiro, G
Format:	Journal article
Language:	English
Published:	2013

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors by Schwartz, G, Carvajal, R, Midgley, R, Rodig, S, Stockman, P, Ataman, O, Wilson, D, Das, S, Shapiro, G

Published 2012

Journal article

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors by Schwartz, G, Carvajal, R, Midgley, R, Rodig, S, Stockman, P, Ataman, O, Wilson, D, Das, S, Shapiro, G

Similar Items